Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

29-07-2021

Alex Baldwin

Is big pharma’s antidote to the COVID-19 waiver a viable alternative?

In May, a consortium of pharmaceutical companies came together to pitch a new plan to help provide more equitable access to COVID-19 vaccines. 


PhRMA, ABPI, BIO, EFPIA, ICBA, IFPMA, Vaccines Europe, COVID-19, WTO, COVAX, TRIPS Agreement, WHO, C-TAP, London School of Economics, USPTO

LSIPR